Bellevue Group AG - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 169 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 1.85 and the average weighting 0.1%.

Quarter-by-quarter ownership
Bellevue Group AG ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$185,000
-6.6%
8,0000.0%0.00%0.0%
Q4 2020$198,000
-99.3%
8,000
-98.9%
0.00%
-99.5%
Q3 2020$29,229,000
-13.5%
704,9760.0%0.40%
-15.5%
Q2 2020$33,775,000
-24.3%
704,976
-0.6%
0.48%
-44.8%
Q1 2020$44,638,000
-49.6%
708,976
-0.9%
0.87%
-38.4%
Q4 2019$88,624,000
+90.2%
715,176
+1.9%
1.40%
+62.1%
Q3 2019$46,596,000
-17.7%
702,176
-1.4%
0.87%
-10.3%
Q2 2019$56,638,000
+2839.2%
711,803
+4031.9%
0.97%
+812.3%
Q1 2019$1,927,000
-17.4%
17,227
-25.6%
0.11%
-30.7%
Q4 2018$2,333,000
-23.5%
23,148
-4.1%
0.15%
-21.1%
Q3 2018$3,051,000
+47.5%
24,148
-2.0%
0.19%
+10.2%
Q2 2018$2,068,000
+5.4%
24,648
-22.7%
0.18%
-9.3%
Q1 2018$1,962,000
+73.2%
31,900
+64.4%
0.19%
+64.4%
Q4 2017$1,133,000
+129.8%
19,400
+128.2%
0.12%
+126.9%
Q3 2017$493,000
-52.1%
8,5000.0%0.05%
-57.4%
Q2 2017$1,029,000
+7.1%
8,5000.0%0.12%
-4.7%
Q1 2017$961,000
+4.0%
8,5000.0%0.13%
-32.3%
Q4 2016$924,000
-58.4%
8,500
-37.0%
0.19%
-52.9%
Q3 2016$2,222,000
+15.4%
13,5000.0%0.40%
+10.8%
Q2 2016$1,926,000
+11.1%
13,5000.0%0.36%
+14.9%
Q1 2016$1,734,00013,5000.32%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q1 2016
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders